Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InspireMD, Inc.NSPR · Entity 7318 | Director · President and CEO | December 16, 2019 | December 17, 2019 |
| Streamex Corp.BSGM · Entity 1816 | Director | August 15, 2023 | August 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InspireMD, Inc.
Report date December 16, 2019 · Filed December 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,166,382 |
Reported balance
After 2019-12-16 transaction · row 1
1 source rowRow 1 · 2019-12-16 · Grant · Acquired 165,000 · Balance 2,166,382 |
Streamex Corp.
Report date August 15, 2023 · Filed August 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,249 |
Reported balance
After 2023-08-15 transaction · row 1
1 source rowRow 1 · 2023-08-15 · Grant · Acquired 12,000 · Balance 71,249 F1: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date May 07, 2018 · Filed May 14, 2018
Section 16 reporting ended · disclosed 2018-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,500 |
Reported balance
After 2018-05-07 transaction · row 1
1 source rowRow 1 · 2018-05-07 · Exercise / conversion · Acquired 12,500 · Balance 12,500 F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-07 · Exercise / conversion · Disposed 12,500 · Balance 0 F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. F2: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc.
F2: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 18, 2023 22:55 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000875 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,249 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:30 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 13,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000399 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,249 F1 · price: Theshares of restricted stock were granted in lieu of remuneration for the Company's 2023 first quarter board fees and shall be fully vested as of April 20, 2023, the date of the grant, based on a closing price of $1.32 per share on such date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:36 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000166 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,091 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's 2022 fourth quarter board fees and shall be fully vested as of February 24, 2023, the date of the grant, based on a closing price of $1.19 per share on such date. Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 01:01 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 34,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-001343 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,091 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's third quarter board meeting and shall be fully vested as of November 18, 2022, the date of the grant, based on a closing price of $0.44 per share. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:05 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000487 · ownership.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:05 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001185185-21-001449 · ownership.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-10-04 F1 · derivative.exercise_date: 50% of the shares underlying this stock option vested and became exercisable immediately on the date of grant and 50% will vest and become exercisable on the first anniversary of the date of the director appointment on September 20, 2022, provided Dr. Barry is still serving as a director on such date and subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 17:56 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-019329 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166,382 Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-001460 · ownership.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,382 Read SEC document |
| May 07, 2018 Filed May 14, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012670 · doc4.xml · derivative · entry 2 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018. F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018. Read SEC document |
| May 07, 2018 Filed May 14, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-012670 · doc4.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. Read SEC document |
| January 26, 2018 Filed Jan 29, 2018 11:25 UTC | InspireMD, Inc. NSPR · Entity 7318 | Tax withholdingCommon Stock | 11 | $0.18 | $1.98 |
DisclosureSEC source: 0001493152-18-001149 · form4.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,376 F1 · shares: Represents shares of restricted shares withheld to pay Mr. Barry's tax withholding obligations incurred in connection with the vesting of 31 shares of restricted stock on January 26, 2018. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:06 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029153 · doc4.xml · derivative · entry 2 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:06 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-029153 · doc4.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 11:53 UTC | InspireMD, Inc. NSPR · Entity 7318 | Tax withholdingCommon Stock | 22,877 | $0.44 | $10,065.88 |
DisclosureSEC source: 0001493152-17-008384 · form4.xml · nonDerivative · entry 2 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,387 F2 · shares: Represents shares of restricted shares withheld to pay Mr. Barry's tax withholding obligations incurred in connection with the vesting of 70,500 shares of restricted stock on August 1, 2017. Read SEC document |
| July 14, 2017 Filed Aug 2, 2017 11:53 UTC | InspireMD, Inc. NSPR · Entity 7318 | Tax withholdingCommon Stock | 65 | $0.45 | $29.25 |
DisclosureSEC source: 0001493152-17-008384 · form4.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,264 F1 · shares: Represents shares of restricted shares withheld to pay Mr. Barry's tax withholding obligations incurred in connection with the vesting of 200 shares of restricted stock on July 14, 2017. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 19:20 UTC | InspireMD, Inc. NSPR · Entity 7318 | Tax withholdingCommon Stock | 12 | $2.44 | $29.28 |
DisclosureSEC source: 0001493152-17-000912 · form4.xml · nonDerivative · entry 1 Barry James J · CIK 0001541253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,349 F1 · shares: Represents shares of restricted shares withheld to pay Mr. Barry's tax withholding obligations incurred in connection with the vesting of 31 shares of restricted stock on January 26, 2017. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 18:03 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-16-035519 · doc4.xml · derivative · entry 1 Barry James J · CIK 0001541253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-21 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.